INT198034

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.17
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
endothelial cell 2
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 7 96.56 Very High Very High Very High
dexamethasone 5 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
Angina 1 5.00 Very Low Very Low Very Low
alcohol 1 5.00 Very Low Very Low Very Low
metalloproteinase 1 5.00 Very Low Very Low Very Low
imagery 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Carcinoma 94 99.26 Very High Very High Very High
INFLAMMATION 7 96.56 Very High Very High Very High
Apoptosis 108 94.52 High High
Hepatocellular Cancer 10 90.96 High High
Disease 11 89.16 High High
Cancer 45 84.00 Quite High
Leukemia 29 78.68 Quite High
Advanced Or Metastatic Breast Cancer 1 74.68 Quite High
Non-small-cell Lung Cancer 1 73.48 Quite High
Colon Cancer 3 71.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The major classes of antiangiogenic therapy include (1) direct anti-VEGF acting molecules (anti-VEGF antibodies, VEGF-antisense nucleotides), (2) immunomodulatory drugs (IMIDs) with antiangiogenic properties, (3) receptor tyrosine kinase inhibitors that target VEGFR signaling as well as receptors of other (proangiogenic) factors, (4) the antiendothelial approach of metronomic therapy, and (5) other new compounds targeting signaling downstream to proangiogenic growth factors, such as mammalian target of rapamycin (mTOR) inhibitors, histone deacetylases' (HDAC) inhibitors, and proteasome inhibitors.
Positive_regulation (direct) of Localization (targeting) of VEGFR
1) Confidence 0.29 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.03 Pain Relevance 0
In 1997, eEPCs were the first putative endothelial progenitors isolated in vitro by culturing CD34+ VEGFR2+ mononuclear blood cells on fibronectin [25] and confirming a subsequent increase in expression of endothelial cell-associated markers such as CD34, CD31, VEGFR2, Tie2, and E-selectin.
Positive_regulation (culturing) of Localization (blood cells) of VEGFR2 in endothelial cell
2) Confidence 0.25 Published 2010 Journal BMC Med Genomics Section Body Doc Link PMC2881111 Disease Relevance 0.19 Pain Relevance 0.05
In contrary, knockdown of Mcl-1 slightly sensitized HCC cells towards inhibition of mTOR by rapamycin (5 nM, 24 h, p < 0.01), selective inhibition of VEGF (Flk-1) and PDGF receptor tyrosine kinases by SU5614 (15 ?
Positive_regulation (by) of Localization (rapamycin) of Flk-1 associated with carcinoma
3) Confidence 0.20 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.96 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox